A Value Framework for Next-Generation Sequencing in Europe: Access to Precision Medicine

By Melike Belenli Gümüş

August 21, 2024

Introduction

Precision medicine stands as a guiding light in cancer care, tailoring treatments to tumour genetics. Next-Generation Sequencing (NGS) and Comprehensive Genomic Profiling (CGP) offer a significant advancement in personalised therapies, outperforming conventional treatments. However, the promise of precision medicine remains unmet without widespread access to essential biomarker testing. To ensure its effective implementation, a robust value framework is essential. A recent article, which has not yet been peer-reviewed, explores the development of a value framework for NGS in Europe, highlighting key criteria and stakeholder consensus.

Bridging the Gap: Value Assessment for Precision Medicine

Traditional Health Technology Assessments (HTAs) are inadequate in evaluating advanced diagnostics like NGS/CGP. These technologies, crucial for treatment decisions, demand a nuanced approach beyond conventional efficacy and safety parameters. The evolving nature of these tests post-approval poses unique regulatory and reimbursement challenges, necessitating adaptable assessment methods.

Despite endorsements from medical societies and initiatives like the EU Beating Cancer Plan, the adoption of NGS in Europe falls behind. Current practices analyse an insufficient percentage of necessary specimens, hindered by funding complexities and unclear value assessments. To fully realise the potential of NGS/CGP technologies, holistic Value Assessment Frameworks (VAFs) are mandatory.

Shaping the Future: A Collaborative Value Framework

A collaborative effort between the London School of Economics (LSE) and the Institute for Clinical Effectiveness and Health Policy (IECS) aimed to adapt a comprehensive VAF for NGS/CGP diagnostics in European oncology. This innovative framework, rooted in stakeholder insights, seeks to address the intricate value dimensions of these advanced diagnostic tools.

Exploring the preferences of diverse healthcare stakeholders, this research uncovers a strong consensus on key criteria, guiding the development of a novel co-created value framework. Addressing the fragmented adoption of NGS/CGP diagnostics in Europe, the study highlights the need for standardisation and equitable access across regions.

Final Framework and Key Findings

The final framework consisted of 23 ‘essential’ sub-criteria and four ‘complementary’ sub-criteria. Two sub-criteria were excluded due to not meeting the inclusion criteria. The framework’s development involved 81 European participants, with a 79% retention rate.

Figure 1: Final Framework.

Embracing Change: Future Directions in Precision Medicine

As precision medicine evolves, the need for a standardised European framework for NGS/CGP value assessment becomes essential. Robust data infrastructure and outcomes-based financing models are critical to ensure equitable access and quality care in personalised medicine. By addressing data governance concerns and societal values, this value framework for NGS sets the stage for informed decision-making in oncology.

Reference url

Recent Posts

Mavyret acute hepatitis C
         

Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implications

🌟 Did you know that the FDA has just approved the first-ever treatment specifically for acute Hepatitis C?

AbbVie’s Mavyret (glecaprevir/pibrentasvir) is now set to improve the way we think about HCV interventions, enabling earlier treatment to reduce long-term complications and improve patient outcomes. This approval not only addresses an urgent public health need but also aligns with evolving healthcare delivery models focused on cost-effective solutions.

Curious to learn more about the implications of this significant advancement in hepatitis care? Review the full article for insightful analysis on the future of HCV treatment!

#SyenzaNews #HealthcareInnovation #MarketAccess #HealthEconomics

HIV vaccine trials
    

Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies

🌍 Are we finally making strides in the fight against HIV?

Recent phase 1 vaccine trials using mRNA technology have shown promising results in activating immune responses that could lead to broadly neutralizing antibodies (bnAbs). This innovative approach not only addresses HIV’s rapid mutation but also offers critical insights for high-prevalence regions.

Dive into the full article to explore how these trials could shape the future of HIV prevention and what it means for global health!

#SyenzaNews #globalhealth #HIV #clinicaltrials

EHK clusters 2026 report
       

EHK Clusters 2026 Report: Enhancements in Dutch Risk Equalization for High-Cost Pharmaceuticals

🚀 Are you curious about how the Dutch healthcare system is adapting to high-cost pharmaceuticals?

The latest EHK clusters report for 2026 brings crucial updates to the risk-equalization model, enhancing equity among health insurers while closely managing skyrocketing costs. With innovative clustering techniques and revised reimbursement figures, these changes aim to improve access and accountability in an increasingly competitive healthcare landscape.

Dive into the full article to uncover the implications for health economics and policy!

#SyenzaNews #HealthEconomics #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.